The Blood Pressure Breakthrough: Mineralys Therapeutics’ Lorundrostat Shows Promise in Treating Uncontrolled Hypertension
In a major breakthrough for the medical community, Mineralys Therapeutics has announced positive topline results from its pivotal Launch-HTN and Advance-HTN trials evaluating the efficacy and safety of lorundrostat for treating uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The company’s stock price has skyrocketed 54.75% in response, making it one of the biggest gainers on … Read more